Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.79 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15688800 | 0.93 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6STS | |
| SCHEMBL2917482 | 0.89 | CYP19A1 (1.00) | CYP19A1MAPTLMNAHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL9382670 | 0.87 | CYP19A1 (0.96) | CYP19A1MAPTLMNAHDAC1HDAC6 | |
| SCHEMBL305828 | 0.87 | CYP19A1 (0.97) | CYP19A1MAPTKDM4EMEN1LMNA | |
| SCHEMBL17159812 | 0.87 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL305950 | 0.86 | CYP19A1 (0.63) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL10172554 | 0.85 | CYP19A1 (1.00) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL15804428 | 0.84 | CYP19A1 (0.61) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL9023539 | 0.82 | CYP19A1 (0.86) | CYP19A1MAPTLMNAHDAC1HDAC6 | |
| SCHEMBL6693307 | 0.81 | CYP19A1 (0.61) | CYP19A1HDAC1HDAC6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966166-B1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LTD (GB) | 2013-01-23 | — | — | EP | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| WO-2007068905-A1 | 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS | STERIX LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
| US-6358984-B1 | FOR THERAPY OF HYPERTENSION AND/OR DISEASES SUCH AS HEART AND RENAL DISEASES | LEAD CHEMICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| US-6358984-B1 | FOR THERAPY OF HYPERTENSION AND/OR DISEASES SUCH AS HEART AND RENAL DISEASES | LEAD CHEMICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| EP-0936221-A4 | NOVEL 2,4-DIOXOPYRROLIDINE AND 2,4-DIOXOTETRAHYDROFURAN DERIVATIVES AND MEDICINES CONTAINING THE SAME AS THE ACTIVE INGREDIENT | LEAD CHEM CO LTD (JP) | 2001-12-19 | — | — | EP | disclosed |
| CN-1074412-C | Novel 2, 4-dioxopyrrolidine and 2, 4-dioxotetrahydrofuran derivatives and drugs containing the same as active ingredient | LEAD CHEM CO LTD (JP) | 2001-11-07 | — | — | CN | disclosed |
| US-6232335-B1 | A BIPHENYL TRIAZOLE COMPOUND USEFUL AS A ANGIOTENSIN II CONVERTING ENZYME INHIBITORS EFFECTIVE IN THE TREATMENT OF HYPERTENSION OR HEART FAILURE | LEAD CHEMICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6232335-B1 | A BIPHENYL TRIAZOLE COMPOUND USEFUL AS A ANGIOTENSIN II CONVERTING ENZYME INHIBITORS EFFECTIVE IN THE TREATMENT OF HYPERTENSION OR HEART FAILURE | LEAD CHEMICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| CN-1234032-A | Novel 2, 4-dioxopyrrolidine and 2, 4-dioxotetrahydrofuran derivatives and drugs containing the same as active ingredient | LEAD CHEM CO LTD (JP) | 1999-11-03 | — | — | CN | disclosed |
| EP-0936221-A1 | NOVEL 2,4-DIOXOPYRROLIDINE AND 2,4-DIOXOTETRAHYDROFURAN DERIVATIVES AND MEDICINES CONTAINING THE SAME AS THE ACTIVE INGREDIENT | LEAD CHEMICAL COMPANY LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| EP-0936221-A1 | NOVEL 2,4-DIOXOPYRROLIDINE AND 2,4-DIOXOTETRAHYDROFURAN DERIVATIVES AND MEDICINES CONTAINING THE SAME AS THE ACTIVE INGREDIENT | LEAD CHEMICAL COMPANY LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| WO-1998012194-A1 | NOVEL 2,4-DIOXOPYRROLIDINE AND 2,4-DIOXOTETRAHYDROFURAN DERIVATIVES AND MEDICINES CONTAINING THE SAME AS THE ACTIVE INGREDIENT | LEAD CHEMICAL CO., LTD. (JP) | 1998-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | CYP19A1, CYP21A2, CBR1 | CYP19A1 1/4885MAPT 4869/4885KDM4E 930/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | CYP19A1 605/4885MAPT 4768/4885KDM4E 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.